Media.Player

Tumor-homing CXCR4-expressing CTLs, Th1 and NK Cells, and Methods of Their Production and Use in Therapy of Cancer and Chronic Infections

Detailed Technology Description

None

*Abstract

The Innovators discovered that hypoxia and small-molecule activators of hypoxia-inducible HIF-1-alpha (hypoxia mimetics) induce double-positive (CXCR4 /GZMB) CD 8 effector T cells. They in turn can migrate to tumor-produced CXCL12 and effectively kill cancer cells.BackgroundEffectiveness of immunity depends on proper homing of functionally-distinct subsets of T cells to different tissues. The ability of cytotoxic CD8 effector T cells (CTL/Teff), Th1- and NK cells to migrate to tumor- and chronically-inflamed tissues is critical for their ability eliminate cancer cells and intracellular infections. The induction of CXCR4 on killer cells could allow them to acquire a Trojan Horse status and exploit the pathway used by the tumors to attract suppressive cells, to enter tumors and kill cancer cells.Benefits1. The cells described by the innovators are simple to generate and require only low-cost procedures or reagents2. In case of hypoxia, no chemicals are used at all, facilitating incorporation of the innovators method into existing protocols 3. The possibility of generating ing cells with mixed phenotype for additional forms of treatment of cancer, infections, allergy, autoimmunity, and transplant rejectionApplicationUS Provisional Application FiledStage of DevelopmentIn Vitro Data

*Principal Investigator

Name: Pawel Kalinski, Assistant Professor of Surgery

Department: Med-Surgery

Name: Ravikumar Muthuswamy

Department: Med-Surgery

Country/Region

USA